BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ribeiro M, Durand T, Roussel M, Feuvret L, Jacob J, Psimaras D, Noel G, Keller A, Bompaire F, Hoang-Xuan K, Bernier MO, Godefroy O, Ricard D. Sensitivity of the Montreal Cognitive Assessment in screening for cognitive impairment in patients with newly diagnosed high-grade glioma. J Neurooncol 2020;148:335-42. [PMID: 32415644 DOI: 10.1007/s11060-020-03524-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Rahman R, Rahman S, Ghani H, Lozada-Martinez ID, Al-Salihi MM, Rahman MM. Letter: Presurgical Identification of Patients With Glioblastoma at Risk for Cognitive Impairment at 3-Month Follow-up. Neurosurgery 2021:nyab282. [PMID: 34318895 DOI: 10.1093/neuros/nyab282] [Reference Citation Analysis]
2 Iqubal A, Iqubal MK, Sharma S, Wasim M, Alfaleh MA, Md S, Baboota S, Ali J, Haque SE. Pathogenic mechanisms and therapeutic promise of phytochemicals and nanocarriers based drug delivery against radiotherapy-induced neurotoxic manifestations. Drug Deliv 2022;29:1492-511. [PMID: 35543534 DOI: 10.1080/10717544.2022.2064562] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Aslanzadeh F, Braun S, Brechbiel J, Willis K, Parker K, Lanoye A, Loughan A. Re-examining popular screening measures in neuro-oncology: MMSE and RBANS. Support Care Cancer 2022. [PMID: 35771290 DOI: 10.1007/s00520-022-07213-0] [Reference Citation Analysis]